분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-06-30 08:16:58 , Hit : 967
 Gilead wins U.S. nod for drug for all types of hepatitis C


Life  |  Tue Jun 28, 2016 2:42pm EDT
Related:  Health  


U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up more than 4 percent.

Gilead said in a separate statement that it priced the drug at $74,760 for a 12-week regimen.

Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi and the combination drug Harvoni. The new treatment, to be sold under the brand name Epclusa, combines Sovaldi (sofosbuvir), which was approved in 2013, with a new anti-viral drug velpatasvir.

Epclusa costs less than the $84,000 that Sovaldi sold for when it launched in late 2013. Gilead now offers discounts and rebates on that older drug, which was at the center of a national uproar over soaring drug costs.

Epclusa is approved for patients with and without cirrhosis, a form of scarring seen in patients with advanced disease that can lead to liver failure and need for a transplant. For those with moderate to severe cirrhosis, Epclusa must be taken with the older drug ribavirin, the Food and Drug Administration said.

"This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C," Edward Cox, director of the FDA's Office of Antimicrobial Products, said in a statement.

While the majority of U.S. patients have the genotype 1 form of hepatitis C, about 20 percent to 25 percent have genotypes 2 or 3, with small numbers infected with genotypes 4, 5 or 6. In other parts of the world, other genotypes are far more prevalent, such as in Egypt, where genotype 4 is widespread.

In pivotal clinical trials, Epclusa led to cure rates of 95 percent to 99 percent in patients without or with mild cirrhosis after 12 weeks of treatment. In a separate trial of patients with moderate to severe cirrhosis, cure rates of 94 percent were seen.

In afternoon trading, Gilead shares were up $3.35, or 4.28 percent at $81.60 on Nasdaq.


(Reporting by Bill Berkrot in New York and Shailesh Kuber in Bengaluru; Editing by Bill Trott and Diane Craft)







967   Revisiting CAR T-Cells for Treating HIV Shows Promise  이성욱 2016/07/19 794
966   코오롱, 유전자치료제 판매 허가 신청  이성욱 2016/07/12 896
  Gilead wins U.S. nod for drug for all types of hepatitis C  이성욱 2016/06/30 967
964   줄기세포·유전자치료제 차세대 주자로 급부상  이성욱 2016/06/21 1124
963   Virus Hacks Host Genome, Steals CRISPR to Protect Itself  이성욱 2016/06/16 835
962   CRISPR Antidotes Galore  이성욱 2016/06/14 1030
961   Let’s Synthesize the Human Genome, Says HGP-Write  이성욱 2016/06/04 851
960   A New CRISPR System for RNA  이성욱 2016/06/04 935
959   Scientists identify a novel CRISPR system that zeroes in on single-stranded RNA.  이성욱 2016/06/04 835
958   GSK gets EU approval for first gene therapy for children  이성욱 2016/05/30 873
957   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 933
956   Mysterious Eukaryote Missing Mitochondria  이성욱 2016/05/17 853
955   Genetically Engineered Pigs May Fly as Cancer Models  이성욱 2016/05/17 922
954   Blame Daddy for Some Epigenetically Induced Birth Defects in Children  이성욱 2016/05/17 932
953   RNA 세상: 태초에 RNA의 퓨린은 어떻게 생성되었나?  이성욱 2016/05/13 1400
952   Three studies show that the virus can cause birth defects in mouse embryos.  이성욱 2016/05/13 1580
951   ‘로렌조 오일’ 유전자 치료로 효과  이성욱 2016/05/09 848
950   First Data from Anti-Aging Gene Therapy  이성욱 2016/04/28 868
949   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1059
948   CRISPR Aids Identification of Sporadic Parkinson’s Mutation in GWAS  이성욱 2016/04/22 843

[이전 10개] [1]..[11][12][13][14][15] 16 [17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN